PTGS2 and hepatocellular carcinoma: We found that the subtilosome-based formulation might deliver COX-2-specific siRNA much more efficiently than the treatment with free siRNA and helped in the regression of the liver enzymes (ALT and AST) in the HCC animals (Figure 4).